Introduction {#s1}
============

Skeletal muscle, the dominant organ for locomotion and energy metabolism, has a remarkable capacity for repair and regeneration in response to injury, disease and aging. Regeneration of adult skeletal muscle following injury occurs through the mobilization of satellite cells (SCs), a population of injury-sensitive quiescent muscle stem cells that activate, proliferate, differentiate, and fuse with injured myofibers. ([@bib4]; [@bib39]). In an adult skeletal muscle, SCs, characterized by expression of the paired box transcription factor Pax7 are mitotically quiescent and reside in a niche between the basal lamina and sarcolemma of associated muscle fibers. In response to muscle damage, SCs are activated and assume a myoblast identity, thereby initiating muscle repair. After massive proliferation, SC-derived myoblasts undergo differentiation and fusion to form myotubes that replace the damaged myofibers ([@bib8]), while a subset of activated satellite cells downregulate MyoD, exit the cell cycle to replenish the muscle stem cell pool.

A large body of studies have shown that a family of four myogenic regulatory factors (MRFs) regulating early skeletal muscle development also regulate the postnatal muscle regeneration program. These MRFs include the myogenic basic-helix-loop-helix type transcription factors MyoD and Myf5, which are recruited to skeletal muscle-specific genes regulatory regions, where they determine myogenic fate and initiate the differentiation cascade. Thereafter, MyoD increases the expression of late target genes in cooperation with myogenin and MRF4 through a feed-forward regulatory mechanism that regulates terminal differentiation ([@bib36]). MRFs also enhance myogenic activity by interacting with other transcription factors, including Mef2 ([@bib15]; [@bib29]).

Although the core MRF network that governs skeletal muscle regeneration and differentiation has been identified, the sequence of events within muscle-specific gene regulatory regions during differentiation is not fully understood. It is highly likely, for example, that the myogenic program driven by MRFs requires input from other transcription factors. More specifically, MRFs, including MyoD, may associate with other transcription factors that respond to microenvironmental cues and restrict the binding of MRFs to particular subsets of target enhancers. This would enable MRF complexes to context dependently regulate muscle genes governing the processes of myocyte differentiation and regeneration. Identification of these MRF partners is therefore important to clarify the mechanism by which MRF-containing transcriptional regulatory complexes achieve precise spatiotemporal regulation of their target genes.

Krüppel-like factors (Klfs) are a subfamily of zinc-finger transcription factors. All Klf proteins contain a DNA-binding domain consisting of three zinc fingers positioned at their carboxyl-terminal end, which enables their specific binding to \'GT-box\' or \'CACCC\' sites ([@bib3]). Several Klf members are involved in the control of skeletal muscle differentiation and function ([@bib37]). For instance, Klf3 is upregulated during skeletal muscle differentiation and transactivates the muscle creatin kinase (*Mck*) promoter ([@bib22]). Klf2 and Klf4 are also upregulated in differentiating muscle cells and promote muscle cell fusion ([@bib46]). Klf6 promotes and Klf10 inhibits myoblast proliferation ([@bib11]; [@bib35]). Klf15 critically regulates skeletal muscle nutrient catabolism, contributing to the regulation of exercise capacity and muscle wasting ([@bib19]; [@bib20]; [@bib43]). These studies demonstrate the pivotal involvement of Klfs in muscle biology. However, their role in the global transcriptional program of muscle differentiation remains unclear. Interestingly, Cao et al. previously showed that binding sites for Sp1, which is structurally related to Klfs and binds to similar GC-rich sequences, are highly enriched in MyoD-binding regions, which suggests there may be interaction between these two transcription factors.

Klf5 is reportedly involved in embryonic development ([@bib44]), control of cellular proliferation and differentiation ([@bib16]; [@bib32]), stress response ([@bib44]), and apoptosis ([@bib54]). *Klf5* null embryos fail to develop beyond the blastocyst stage *in vivo* or to produce embryonic stem cell lines *in vitro*, indicating that Klf5 is essential for maintenance of stemness ([@bib13]; [@bib44]). Klf5 is expressed in many cell types, including gut epithelial cells ([@bib6]; [@bib45]), vascular smooth muscle cells ([@bib16]), adipocytes ([@bib32]), neuronal cells ([@bib51]) and leukocytes ([@bib52]). In smooth muscle cells, Klf5 regulates the genes involved in early processes of differentiation, including SMemb/NMHC-B and SM22α ([@bib1]; [@bib50]). Klf5 is also required for adipocyte differentiation. In 3T3-L1 preadipocytes, Klf5 is induced at an early stage of differentiation by C/EBPβ and δ, which is followed by expression of PPARγ~2~ ([@bib32]). We previously reported that Klf5 acts as a regulator of lipid metabolism in skeletal muscle ([@bib33]). However, the role of Klf5 in skeletal muscle differentiation has not been characterized. In the present study, therefore, we investigated the role of Klf5 in skeletal muscle differentiation and regeneration.

Results {#s2}
=======

Klf5 is highly expressed in differentiating myoblasts during muscle regeneration {#s2-1}
--------------------------------------------------------------------------------

To test the hypothesis that Klf5 is involved in skeletal muscle regeneration, we first examined tibialis anterior (TA) muscle from C57BL/6J wild-type mice with and without cardiotoxin (CTX)-induced skeletal muscle injury ([@bib26]). As compared to expression in intact (uninjured) muscle, expression of *Klf5* mRNA in regenerating TA muscles was upregulated 2 and 4 days after injury, as was expression of myogenic factors (*Pax7, Myod1, Myog* and *Myh3*) ([Figure 1A](#fig1){ref-type="fig"}).10.7554/eLife.17462.002Figure 1.Klf5 is upregulated during myogenesis.(**A**) Relative mRNA expression of *Klf5, Pax7, Myod1, Myog* and *Myh3* (embryonic myosin heavy chain) in intact and regenerating TA muscles. The animals were sacrificed on day 4 after CTX injection. Data are means ± SEM. \*\*\*p\<0.001. \*\*p\<0.01. Representative data from three individual mice are shown. (**B**) Klf5 expression during muscle regeneration. Klf5 was not detectable in quiescent satellite cells (SCs) in intact muscle (arrows in the top panels). During muscle regeneration, Klf5 was highly expressed in the nuclei of differentiating myocytes expressing Myog (arrowheads) and regenerating myofibers, whereas Klf5 expression was not detected or detected very weakly in Pax7-positive SCs (arrows). Representative data from at least three individual mice are shown. Scale bar represents 20 µm. (**C**) Plated SCs were cultured in growth medium (GM) or differentiating medium (DM; for 2 days or 4 days) after isolation and were co-immunostained for Klf5 with Pax7 or Myog. Klf5 is expressed in the differentiating myocytes, which were negative or very weakly positive for Pax7 (arrows). Klf5 was upregulated during differentiation and frequently co-localized with Myog. After 4 days of culture, Klf5 levels were decreased in the nuclei of large myotubes (arrowheads). Representative data from at least three individual mice are shown. Scale bar represents 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.002](10.7554/eLife.17462.002)10.7554/eLife.17462.003Figure 1---figure supplement 1.Preparation of SC primary cultures.(**A**) Isolated EDL myofibers with their associated SCs were immediately fixed and immunostained for Pax7 and Klf5. (**B**) SCs were prepared from EDL muscles from wild-type C57/B6 mice and stained for Pax7 and MyoD. (**C--D**) Proportion of Pax7^+^, Pax7^+^: MyoD^+^ and MyoD^+^ cells (**C**) or Pax7^+^, Pax7^+^: Klf5^+^ and Klf5^+^ cells (**D**) in the primary SCs cultured in the growth media (GM). Expression of MyoD in every analyzed cells, indicating these cells are composed of pure, myoblast-lineage population. Pax7^+^: MyoD^-^ cells was not detected. (**E**) Two days post differentiation, propotion of Myog^+^, Myog^+^: Klf5^+^ and Klf5^+^ cells were analyzed. Note that all the Myog positive cells were also positive for Klf5. Data represent means ± SEM. Representative data from at least three individual mice are shown. DM: differentiation medium.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.003](10.7554/eLife.17462.003)

Our immunohistochemistry results showed that little or no Klf5 is expressed in Pax7-positive, quiescent SCs or myonuclei that constitute intact muscle ([Figure 1B](#fig1){ref-type="fig"} upper panel, [Figure 1---figure supplement 1A](#fig1){ref-type="fig"}). Seven days after CTX-induced muscle injury, we observed ongoing muscle regeneration characterized by the presence of centrally located nuclei in regenerating fibers. At that time, expression of Klf5 remained very low in Pax7-positive, activated SCs ([Figure 1B](#fig1){ref-type="fig"}, middle panel, arrows). However, higher levels of Klf5 were detected in differentiating myocytes, which expressed myogenin 7 days after injury ([Figure 1B](#fig1){ref-type="fig"}, lower panel, arrowheads). Klf5 was also detected within the centrally located nuclei of regenerating myofibers. These results indicate that Klf5 is markedly upregulated in differentiating myocytes and regenerating myofibers during the course of muscle regeneration *in vivo*.

To examine Klf5 expression during muscle differentiation *in vitro*, SCs were isolated from the extensor digitorum longus (EDL) muscle from wild-type mice and placed in culture. After the first passage, nearly 100% of cells were MyoD positive, confirming the high purity of the muscle cell cultures ([Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}). Over 70% of the purified cells were also positive for Pax7 ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Consistent with the *in vivo* results, little or no Klf5 was detected in a fraction of the activated SCs expressing Pax7 and MyoD ([Figure 1C](#fig1){ref-type="fig"}, upper panel). Approximately 75% of Pax7-positive cells were also weakly positive for Klf5 ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Klf5 was induced in differentiating myoblasts exhibiting an absence or low Pax7 expression ([Figure 1C](#fig1){ref-type="fig"}, arrows, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). After differentiation for 2 days, Klf5 was strongly expressed in the nuclei of differentiating myotubes and co-localized with myogenin ([Figure 1C](#fig1){ref-type="fig"}, middle panel, [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). However, the strong Klf5 expression was transient, and by day 4 of differentiation it was undetectable in the nuclei of larger, fused myotubes that had also lost myogenin expression ([Figure 1C](#fig1){ref-type="fig"}, arrowheads). These *in vitro* observations indicate that Klf5 is induced in differentiating myoblasts during muscle differentiation and then downregulated in mature myotubes.

Klf5 is required for muscle regeneration {#s2-2}
----------------------------------------

The finding of temporal overlap between Klf5 expression and muscle regeneration and differentiation *in vivo* and *in vitro* prompted us to examine the role of Klf5 in SC-mediated muscle regeneration *in vivo*. Mice carrying floxed *Klf5* alleles with loxP sites were crossbred with mice expressing *Pax7*-driven CreERT2, a tamoxifen-inducible recombinase to generate *Pax7^CE/+^;Klf5^flox/flox^*mice. The *Pax7^CE/+^* mice were previously shown to be able to ablate almost 100% of SCs when crossed with *R26R^GFP-DTA/+^*mice ([@bib26], [@bib27]). The *Pax7^CE/+^;Klf5^flox/flox^* model enabled us to selectively delete *Klf5* from SCs after tamoxifen injection. To induce SC-specific *Klf5* deletion, 8- to 12-week-old *Pax7^CE/+^;Klf5^flox/flox^* mice were treated with tamoxifen for 5 days before use in subsequent experiments. Control *Pax7^+/+^;Klf5^flox/flox^* mice were also treated with tamoxifen. Hereafter, *Pax7^CE/+^;Klf5^flox/flox^* and *Pax7^+/+^;Klf5^flox/flox^* mice will represent the mice treated with tamoxifen in this manner. Muscle histology revealed that *Pax7^CE/+^;Klf5^flox/flox^* mice or control *Pax7^+/+^;Klf5^flox/flox^* mice displayed no obvious phenotypic alterations under physiological conditions and exhibited no morphological alterations in their skeletal muscle stained with hematoxylin and eosin (H&E) 28 days after tamoxifen treatment ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

After continuous tamoxifen administration for 5 days, CTX was injected into the TA muscles of both *Pax7^CE/+^;Klf5^flox/flox^* and control *Pax7^+/+^;Klf5^flox/flox^* mice, which were then analyzed 4, 7 and 28 days after injury. On day 4 after injury, mRNA expression of *Myog* and *Myh3* was significantly lower in regenerating muscles from *Pax7^CE/+^;Klf5^flox/flox^* mice than control mice; *Pax7* and *Myod1* levels also tended to be reduced, but the differences did not reach statistical significance ([Figure 2A](#fig2){ref-type="fig"}). On day 7 after injury, H&E and immunofluorescent staining in control mice revealed efficient muscle regeneration characterized by regenerated myofibers with decreased expression of eMyHC, a marker of immature myofibers ([Figure 2B](#fig2){ref-type="fig"}). On the contrary, the regeneration process was significantly impaired in *Pax7^CE/+^;Klf5^flox/flox^* mice. These mice exhibited necrotic fibers and infiltrating inflammatory cells, and an extensive area of regenerating myofibers with prolonged expression of eMyHC ([Figure 2B and C](#fig2){ref-type="fig"}). Analysis of the distribution of myofiber diameters revealed that *Klf5* deletion in SCs significantly shifted regenerating myofibers towards smaller diameters ([Figure 2D](#fig2){ref-type="fig"}), suggesting differentiation and/or maturation of muscle fibers were impaired by the loss of Klf5.10.7554/eLife.17462.004Figure 2.Klf5 is required for muscle regeneration *in vivo*.CTX was injected into the TA muscles of SC-specific *Klf5* knockout mice (*Pax7^CE/+^;Klf5^flox/flox^*) and control *Pax7^+/+^;Klf5^flox/flox^* mice. The animals were then sacrificed on day 4 (**A**), 7 (**B**--**D**) or 28 (**E**--**F**) after CTX injection. (**A**) *Pax7, Myod1, Myog* and *Myh3* expression in regenerating TA muscle (on day 4 after CTX injection) was analyzed using qRT-PCR (**A**). Data represent means ± SEM. n = 3 for each group. \*\*p\<0.01. N.S., not significant. (**B--F**) Sections were stained with H&E or immunostained for eMyHC, laminin and collagen I. Representative images of muscle sections on day 7 (**B**) or 28 (**E**) after CTX injection are shown. The eMyHC-positive area 7 days after CTX injection was quantified using Olympus cellSense Digital Imaging software (**C**). Distributions of myofiber diameters on days 7 (**D**) and 28 (**F**) after CTX injection are shown. Representative data from four *Klf5* knockout and five control (for day 7) or four mice for each genotype (for day 28) are shown. Scale bars represent 100 µm. \*\*\*p\<0.001. \*\*p\<0.01. N.S., not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.004](10.7554/eLife.17462.004)10.7554/eLife.17462.005Figure 2---figure supplement 1.Tamoxifen treatment does not affect TA muscle morphology.TA muscles were obtained from Klf5 knockout mice (*Pax7^CE/+^; Klf5^flox/flox^*) and control *Pax7^+/+^; Klf5^flox/flox^* mice on day 28 after tamoxifen injection. Muscle morphology was assessed by H--E staining.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.005](10.7554/eLife.17462.005)

Twenty-eight days after CTX injury in control mice, muscle regeneration was nearly complete, as evidenced by the presence of regenerated, mature fibers and disappearance of inflammatory cells, as previous described ([@bib23]). However, the regeneration process was retarded in the injured muscle of *Pax7^CE/+^;Klf5^flox/flox^* mice, and massive deposition of collagen I, indicating enhanced fibrosis, was observed ([Figure 2E](#fig2){ref-type="fig"}). In addition, the regenerating myofibers were still shifted toward smaller diameters ([Figure 2F](#fig2){ref-type="fig"}). These results indicate that Klf5 is required for proper SC-mediated muscle regeneration after skeletal muscle injury.

Klf5 is required for myoblast differentiation {#s2-3}
---------------------------------------------

The molecular mechanism responsible for muscle regeneration mimics that for skeletal muscle differentiation, and the compromised muscle regeneration after SC-selective *Klf5* deletion suggested to us that Klf5 is necessary for proper skeletal muscle cell differentiation. To test that idea, we used C2C12 myoblasts, a widely-employed cell line that retains the potential to differentiate into myotubes. *Klf5* mRNA was induced after induction of C2C12 cells differentiation and reached a peak on day 4 of myoblast differentiation ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Klf5 protein was detected after 2 days of differentiation ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) and was frequently colocalized with myogenin in the nuclei of differentiating myotubes, which is consistent with the pattern observed during myogenic differentiation of SCs ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"} and [Figure 1C](#fig1){ref-type="fig"}).

To test the requirement for Klf5 in myoblast differentiation, we generated *Klf5*-null C2C12 cells using a CRISPR-Cas9 system ([@bib38]). Three *Klf5*-null clones and three control clones were established ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), and it was confirmed that both alleles were targeted by deletion and/or frame-shift mutation at the target loci in the *Klf5*-null clones ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Klf5 protein was not detectable after induction of differentiation in any of the three *Klf5*-null clones ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), and myotube formation was significantly impaired as compared to the control clones ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). This effect occurred concomitantly with decreased expression of myogenin and MyHC on day 4 of differentiation ([Figure 3A--C](#fig3){ref-type="fig"}). To determine whether forced expression of Klf5 could rescue the compromised differentiation of *Klf5*-null clones, Klf5 was exogenously introduced using a retrovirus harboring murine Klf5 (RV-Klf5). *Klf5*-null C2C12 cells transfected with RV-Klf5 successfully formed myotubes when stimulated to differentiate, whereas *Klf5*-null cells infected with an empty retrovirus failed to do so ([Figure 3D](#fig3){ref-type="fig"}). In addition, immunohistochemistry and western blotting demonstrated that expression of MyHC and myogenin was partially rescued by the forced expression of Klf5 ([Figure 3D--F](#fig3){ref-type="fig"}). Klf5 thus appears to be required for a myoblast differentiation.10.7554/eLife.17462.006Figure 3.Klf5 is essential for muscle differentiation.(**A**) Establishment of *Klf5* knockout (KO) myoblasts using a CRISPR-Cas9 system. *Klf5* KO C2C12 cells or Control cells were immunostained for MyHC and Klf5 or myogenin. *Klf5* KO cells do not express Klf5 during muscle differentiation and exhibit severely reduced myotube formation. MyHC: myosin heavy chain, Myog: myogenin. Scale bar represents 100 µm. (**B**) Percentage of Myog-positive cells among total cells. *Klf5* KO cells exhibited less Myog expression than Control. Data are means ± SEM. (\*\*\*p\<0.001) Representative data from at least three individual experiments are shown. (**C**) Western blots showing reduced MyHC and Myog expression in *Klf5* KO C2C12 cells during differentiation. Representative data from at least three individual experiments are shown. (**D**) *Klf5* KO cells were infected with a Retro-viral vector (RV-Klf5) harboring *Klf5* or empty vector (RV-control), after which differentiation was induced for 2 or 4 days. The cells were then fixed and immunostained for Klf5 or MyHC. Impairment of myotube formation, as evidence from the loss of MyHC expression in *Klf5* KO cells was rescued by exogenous Klf5 expression. Representative data from at least three individual experiments are shown. (**E--F**) Western blots revealing the reduction of MyHC and Myog expression in *Klf5* KO C2C12 cells and its rescue by RV-Klf5. The expression levels were normalized to β-Tubulin (**F**). Data represent means ± SEM. (\*\*p\<0.01) Representative data from at least three individual experiments are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.006](10.7554/eLife.17462.006)10.7554/eLife.17462.007Figure 3---figure supplement 1.*Klf5* knockdown impairs myoblast differentiation.(**A**) *Klf5* expression during C2C12 differentiation. Bars depict means ± SEM. n = 3, biological replicates. GM: growth medium, DM: differentiation medium. (**B**) Induction of Klf5 expression during C2C12 differentiation was assessed immunostaining for MyHC and Klf5. Klf5 is highly expressed in the nuclei of differentiating myoblasts expressing MyHC and in myotubes. However, little Klf5 expression was seen in proliferating C2C12 cells in GM. Representative data from at least three individual experiments are shown. MyHC: Myosin heavy chain. Scale bar represents 100 µm. (**C**) Relative mRNA expression of Klf family members in C2C12 myotube on day 3 by QPCR. Bars depict means ± SEM. \*\*\*\*p\<0.0001, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05, N.S., not significant. n = 3, biological replicates.　**DOI:** [http://dx.doi.org/10.7554/eLife.17462.007](10.7554/eLife.17462.007)10.7554/eLife.17462.008Figure 3---figure supplement 2.Establishment of *Klf5* knockout C2C12 cells.(**A**) C2C12 cells were transfected with pSpCas9-Klf5 or GFP-targeted control vector. After puromycin selection, the cells were cloned using the limiting dilution method. Three *Klf5* knockout (KO) clones and three control C2C12 clones were obtained. *Klf5* KO was confirmed by the absence of immunofluorescence. Compared to the control cells, all *Klf5* KO cells exhibited defective myotube formation, as indicated by MyHC staining. Scale bar represents 100 µm. (**B**) Confirmation of mutation in the *Klf5* gene locus. The position of guide RNA is indicated by the blue boxes. The red boxes indicate deleted sequences in the mutant allele, and the white \# in the red box indicates the substituted nucleotide in the mutant allele. Clones \#1 and \#3 have a 1-bp deletion mutation in both alleles. The one allele of the clone \#2 contains a 33-bp deletion, and the other allele contains a 33-bp deletion plus a 1-bp substitution mutation.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.008](10.7554/eLife.17462.008)10.7554/eLife.17462.009Figure 3---figure supplement 3.Phenotype of *Klf5* knockdown cells.(**A**--**C**) Klf5, myogenin (Myog), and MyHC expression in C2C12 cells after siRNA treatment. C2C12 cells were treated with either siKlf5 or siControl (siCtrl). After siRNA treatment in GM for 24hr, the medium was replaced with DM. After 2 days in DM, the cells were fixed and co-immunostained. Note the ratio of Myog-positive cell was significantly decreased by siKlf5 treatment (**B**). Data represent means ± SEM. (\*p\<0.05) Representative data from at least three individual experiments are shown. (**D**) Fusion index indicating fibers containing more than 3 nuclei. The fusion index was significantly reduced in cells transfected with siKlf5, though similar levels of MyoD positivity was detected. Data represent means ± SEM. (\*\*\*p\<0.001) Representative data from at least three individual experiments are shown. Scale bar represents 100 µm. N.D.: not detected. (**E**) Growth curve of siCtrl- and siKlf5-treated C2C12 cells in GM. Data represent means ± SEM. Representative data from four individual experiments are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.009](10.7554/eLife.17462.009)

This requirement for Klf5 in myoblast differentiation was further confirmed by knocking down *Klf5* using specific small interfering RNA (siRNA) in C2C12 cells. Immunohistochemistry indicated that the *Klf5* knockdown efficiently inhibited the induction of myogenin ([Figure 3---figure supplement 3A and B](#fig3s3){ref-type="fig"}). At the same time, myotube formation was significantly impaired in the *Klf5* knockdown cells, as quantified based on the Fusion index, which represents the fraction of MyHC-positive, fused myotubes that contain at least three nuclei ([Figure 3---figure supplement 3C and D](#fig3s3){ref-type="fig"}). Although previous reports have shown the involvement of Klf5 in controlling cell proliferation in several cancer cell lines ([@bib45]), *Klf5* knockdown did not affect C2C12 cell proliferation ([Figure 3---figure supplement 3E](#fig3s3){ref-type="fig"}).

Because previous studies have shown cooperation and competition among Klf members ([@bib46]), we analyzed the effects of *Klf5* knockdown on expression of other Klf members. Levels of *Klf6, Klf13, Klf15*, and *Klf16* expression were modestly, but significantly, increased in *Klf5* knockdown cells on day 3 ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). On the other hand, expression of *Klf10* and *Klf11* was decreased in *Klf5* knockdown cells.

Klf5 is required for induction of myogenesis-related genes {#s2-4}
----------------------------------------------------------

The observation that Klf5 is required for myoblast differentiation in both SCs and C2C12 cells led us to examine the consequences of *Klf5* knockdown on a genome-wide scale. A series of RNA-seq analyses of differentiating myoblasts and myotubes transfected with siRNA targeting Klf5 or control RNA were performed. In line with the suppressed myoblast differentiation, expression of a set of genes involved in myogenesis was significantly decreased in *Klf5* knockdown cells ([Figure 4A](#fig4){ref-type="fig"}). Among the 12,744 expressed transcripts (normalized counts \>4), 1472 with RefSeq annotations were reduced by \>1.5-fold on day 3 in the *Klf5* knockdown cells as compared to the control cells. Gene ontology analysis revealed that the genes whose expression was reduced by *Klf5* knockdown had significant enrichment of functional annotations for myogenesis and muscle cell development ([Figure 4B](#fig4){ref-type="fig"}). Among the 934 genes exhibiting a \>1.5-fold increase in expression in *Klf5* knockdown cells, no gene sets directly related to myogenesis were significantly enriched as compared to control cells on day 3 ([Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}).10.7554/eLife.17462.010Figure 4.Transient *Klf5* knockdown results in a repression of the myogenic program.(**A**) Hierarchical clustering and heatmap of the expression levels (log2 normalized counts) of genes involved in the Hallmark Myogenesis (hallmark gene sets M5909) in C2C12 myoblasts transfected with control or *Klf5*-specific siRNA after induction of differentiation for the indicated times. (**B**) Functional annotations associated with genes that were inhibited in *Klf5* knockdown cells. (**C**) Relative distribution of RNA-seq tags of genes with MyoD binding during the course of myoblast differentiation. Box-and-whisker plot showing log2 counts of the MyoD-regulated genes and the remaining RefSeq genes normalized to the counts in control siRNA-transfected cells on day 0. P values are between control siRNA (Ctrl) and siKlf5 (KD) cells analyzed using the Mann-Whitney *U* test. (**D**) MA plot depicting the relationship between fold changes in myotube differentiation-related genes, comparing RNA-seq from differentiating myoblasts transfected with control siRNA or siRNA targeting Klf5. Red dots represent genes with MyoD binding, and the Gray dots represents genes without MyoD binding. (**E**) UCSC genome browser images illustrating normalized RNA-seq reads for the representative myogenesis-related genes *Myog* and *Myl4* in control or Klf5 siRNA-transfected C2C12 cells at the indicated days after induction of differentiation. (**F**) Relative mRNA expression of *Klf5, Myog, Mybph, Myl4* and *Myom2* in C2C12 cells transfected with control siRNA or siRNA targeting Klf5. Data represent means ± SEM. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, n = 3, biological replicates). (**G**) *de novo* motifs identified in regions bound by MyoD in myotubes. The enrichment for a known Sp1 motif was also analyzed.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.010](10.7554/eLife.17462.010)10.7554/eLife.17462.011Figure 4---source data 1.Gene ontology analysis on the genes upregulated by *Klf5* knockdown.Functional annotations associated with genes that were induced \>1.5-fold with *Klf5* knockdown at day 3 post differentiation.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.011](10.7554/eLife.17462.011)

We next assessed the effects of *Klf5* knockdown on MyoD-regulated genes. Analysis of MyoD binding sites using previously reported MyoD ChIP sequencing (ChIP-seq) of C2C12 myotubes differentiated for 2 days ([@bib5]) revealed that among the Refseq genes, 753 that contained nearby sites bound by MyoD were upregulated by \>two-fold on day 3 as compared with day 0. These genes are most likely direct MyoD targets and are highly enriched with myogenesis-related genes. The effect of *Klf5* knockdown on the expression of MyoD-regulated genes became more pronounced as the course of differentiation proceeded ([Figure 4C](#fig4){ref-type="fig"}), and expression of those MyoD-regulated genes on day 3 was significantly decreased by *Klf5* knockdown ([Figure 4C and D](#fig4){ref-type="fig"}). This distinct pattern of gene expression is exemplified by *Myog* and *Myl4* ([Figure 4E](#fig4){ref-type="fig"}). Quantitative PCR analysis confirmed that expression of MyoD-regulated genes, as exemplified by *Myog, Mybph, Myl4* and *Myom2*, was significantly decreased by *Klf5* knockdown in C2C12 cells on day 3 post-differentiation ([Figure 4F](#fig4){ref-type="fig"}). This indicates that Klf5 is required for expression of these MyoD-regulated genes. Remarkably, *de novo* motif analysis revealed that the top motifs in the MyoD-bound cistrome included ones closely matched with known consensus myogenin (E-box), Mef2 and Klf5 binding motifs, which suggests potential co-localization of MyoD, Mef2 and Klf5 at MyoD-regulated enhancers ([Figure 4G](#fig4){ref-type="fig"}). Cao et al. previously showed that the motif for Sp1 is enriched in regions bound by MyoD ([@bib5]). The previously identified Sp1 motif contains a core 5'-CCGCCC-3' sequence, which matches a subset of the Klf motif ranked as 4th in our de novo motif analysis. This suggests the Sp1 motif may also be enriched. Indeed, enrichment analysis of a known Sp1 motif showed that the Sp1 motif is enriched in the MyoD binding regions ([Figure 4G](#fig4){ref-type="fig"}).

Klf5 regulates myogenesis-related genes in concert with MyoD and Mef2 {#s2-5}
---------------------------------------------------------------------

The observation that the MyoD-bound cistrome was significantly enriched in the KLF5 motif led us to test the hypothesis Klf5 regulates genes involved in myogenesis in concert with MyoD and Mef2. To investigate the location of Klf5 during the course of myoblast differentiation, we performed ChIP-seq using a Klf5 specific antibody. In addition, we used published ChIP-seq data to analyzed the binding sites of Mef2D in C2C12 myotube on day 5, the major Mef2 isoform involved in expression of late muscle-specific genes ([@bib41]). As expected, Klf5 bound to the regulatory regions of myogenesis-related genes, as exemplified by *Myog, Myod1, Myl4* and *Mybph*, throughout the course of differentiation ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). MyoD and Mef2D binding was frequently observed at those gene loci. The recruitment of Klf5, MyoD and Mef2 to the *Myog* enhancer was further confirmed using ChIP-QPCR ([Figure 5---figure supplement 2A--C](#fig5s2){ref-type="fig"}).10.7554/eLife.17462.012Figure 5.Klf5 regulates myogenesis-related target genes in concert with MyoD.(**A**) UCSC genome browser images illustrating normalized tag counts for Klf5 (post-differentiation day 0, 2, 5), MyoD (myotube, differentiated for 2 days) and Mef2D (myotube, differentiated for 5 days) at *Myog* loci in differentiating C2C12 myotubes. (**B**) Heatmap for binding of Klf5 (post-differentiation day 0, 2, and 5), MyoD (myotubes, differentiated for 2 days) and Mef2D (myotubes, differentiated for 5 days) within 2 kb around the center of the top 1000 Klf5-binding sites on day 5. The Klf5 binding sites were subdivided into 2 groups based on the presence of significant MyoD binding peaks in myotubes within 500 bp of the Klf5 binding regions. The distribution of Klf5 tag densities in each subgroup were shown as histogram. (**C**) Distribution of Klf5 tag densities in the vicinity of MyoD-bound loci in myoblasts differentiated for 0, 2 and 5 days. (**D**) Distribution of Klf5 tag densities in the vicinity of Mef2D-bound loci in myoblasts differentiated for 0, 2 and 5 days. (**E**) Venn diagram showing the overlap between the 12,769 MyoD peaks, 11,193 Mef2D peaks and 4382 Klf5 peaks identified by ChIP-seq. Note over half the Klf5 peaks (2224 out of 4382 peaks) are also bound by MyoD and/or Mef2. (**F**) Direct interaction of Klf5 and MyoD or Mef2 shown by co-immunoprecipitation. Whole cell extract from C2C12 cells differentiated for 5 days were immunoprecipitated using anti-MyoD or anti-Mef2 antibody. The interaction between Klf5 and MyoD or Mef2 is shown compared to the 1% Input or control samples without primary antibodies. (**G**) de novo motifs identified in regions bound by Klf5 in myotubes after differentiation for 5 days. (**H**). HEK-293T cells were co-transfected with *Myog*-luciferase; Klf5, MyoD, and Mef2D expression plasmids, as indicated; and a control CMV-renilla luciferase plasmid. Luciferase activities relative to the basal level of *Myog*-luciferase cotransfected with empty expression vectors are shown. Data represent means ± SEM. (\*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001). Representative data from three individual experiments are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.012](10.7554/eLife.17462.012)10.7554/eLife.17462.013Figure 5---figure supplement 1.Klf5, MyoD and Mef2D are colocalized in the myogenesis-related gene loci.UCSC genome browser images illustrating normalized tag counts for Klf5 (post differentiation day 0, 2, 5), MyoD (myotubes, differentiated for 2 days) and Mef2D (myotubes, differentiated for 5 days) at *Myod1, Mybph* and *Myl4* loci in C2C12 myotubes.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.013](10.7554/eLife.17462.013)10.7554/eLife.17462.014Figure 5---figure supplement 2.MyoD and Klf5 are recruited to the E-box-containing enhancer of the *Myog* locus.Recruitment of MyoD (**A**), Klf5 (**B**) and Mef2 (**C**) to the *Myog* promoter was monitored using ChIP assays with chromatin prepared from C2C12 myoblasts after differentiation for 0, 2 or 5 days. The *Gapdh* locus served as a negative control. n = 3, biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.014](10.7554/eLife.17462.014)10.7554/eLife.17462.015Figure 5---figure supplement 3.Klf5 binding regions in undifferentiated myoblasts.Heatmap for binding of Klf5 (post-differentiation day 0, 2, and 5), MyoD (myotubes, differentiated for 2 days) and Mef2D (myotubes, differentiated for 5 days) within 2 kb around the center of the top 1000 Klf5-binding sites on day 0. The Klf5 binding sites were subdivided into 2 groups based on the presence of significant MyoD binding peaks in myotubes within 500 bp of the Klf5 binding regions. The distribution of Klf5 tag densities in each subgroup were shown as histogram.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.015](10.7554/eLife.17462.015)

[Figure 5B](#fig5){ref-type="fig"} shows a heatmap of Klf5, MyoD, and Mef2D binding around the top 1000 Klf5 binding peaks in C2C12 myotubes on day 5. Approximately half of the Klf5 peaks had significant MyoD binding peaks in close proximity. An association with Mef2D was also observed in many Klf5 binding regions. Consistent with these findings, genome-wide binding profiles showed that there is significant overlap among the Klf5, MyoD and Mef2D cistromes ([Figure 5C and D](#fig5){ref-type="fig"}). Among 4382 Klf5 peaks observed on day 5 post-differentiation, 757 loci (17.2%) were also bound by both MyoD and Mef2D, and another 1467 sites (33.4%) were bound by either MyoD or Mef2D ([Figure 5E](#fig5){ref-type="fig"}). Moreover, Klf5 binding to the MyoD and Mef2D binding peaks increased as differentiation progressed ([Figure 5C and D](#fig5){ref-type="fig"}, compare day 0 vs. day 2 and 5). Co-immunoprecipitation showed that Klf5 directly associated with MyoD and Mef2 *in vitro* ([Figure 5F](#fig5){ref-type="fig"}). These results suggest that Klf5, MyoD and Mef2 work together to drive expression of a set of genes involved in myogenic differentiation.

Only a small fraction of the regions that had Klf5 binding before differentiation (day 0) had significant MyoD binding in close proximity after starting differentiation into myotubes ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). This is in contrast to the Klf5-bound regions on day 5 ([Figure 5B](#fig5){ref-type="fig"}), which showed strong association with MyoD. The association of Klf5 with loci at which Klf5 was already bound before starting differentiation (day 0) was decreased or unchanged over the course of differentiation ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). This was in sharp contrast to the association of Klf5 recruited after starting myogenic differentiation ([Figure 5B](#fig5){ref-type="fig"}). Collectively then, a majority of regions that increasingly acquire Klf5 binding during differentiation are also bound by MyoD in proximity to the Klf5 within myotubes. On the other hand, at many observed Klf5 binding regions in myoblasts, binding is decreased during differentiation and not associated with MyoD binding within myotubes. These results suggest that Klf5 has different targets and functions in myoblasts vs. myotubes. Because this study focuses on Klf5's function during muscle differentiation and regeneration, we will characterize Klf5 binding mainly in myotubes.

Analysis of Klf5-bound motifs revealed that the top motif among the Klf5 cistrome matches the consensus of Krüppel-like factor ([Figure 5G](#fig5){ref-type="fig"}). The Myf5 (E-box consensus bound by MRF, including MyoD) and Mef2D motifs were also identified in the de novo motif analysis, suggesting that colocalization of Klf5, MyoD and Mef2 are programmed by cis-regulatory logic. These results demonstrate a significant role for Klf5 in myogenic differentiation, acting in coordination with two other myogenic transcription factors, MyoD and Mef2.

To assess the functional significance of Klf5 in the regulation of muscle-specific target genes, we performed luciferase assays ([Figure 5H](#fig5){ref-type="fig"}). To eliminate effects of endogenous MyoD and Mef2D expression, HEK293T cells were co-transfected with Klf5, MyoD, Mef2D and *Myog* promoter-luciferase plasmids, which contained the proximal promoter region bound by Klf5, MyoD and Mef2 determined from each ChIP-seq ([Figure 5B](#fig5){ref-type="fig"}). We found that Klf5 alone activated the *Myog* reporter. Moreover, Klf5, MyoD and Mef2D activated the *Myog* reporter additively ([Figure 5H](#fig5){ref-type="fig"}). Together, these findings indicate that Klf5 is an active transcription factor for myogenesis, cooperating with MyoD and Mef2.

Klf5 is necessary for the recruitment of MyoD to muscle-specific target genes {#s2-6}
-----------------------------------------------------------------------------

Our results indicate that the Klf5 cistrome significantly overlaps those of MyoD and Mef2 ([Figure 5A--E](#fig5){ref-type="fig"}), and Klf5 directly interacts with MyoD and Mef2 ([Figure 5F](#fig5){ref-type="fig"}). In addition, the compromised myogenic phenotype observed in *Klf5* knockout SCs and C2C12 cells ([Figures 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}), and the reduction in the fraction of MyoD-regulated gene expression induced by *Klf5* knockdown in differentiating C2C12 cells ([Figure 4C,D](#fig4){ref-type="fig"}), also suggest Klf5 affects MyoD-dependent gene regulation. To test whether Klf5 is required for recruitment of MyoD to target sites, we performed ChIP-seq of MyoD in *Klf5-*null and GFP-targeted control C2C12 myotubes to determine the effects of the *Klf5* deletion on the MyoD cistrome. Although levels of MyoD and Mef2 protein were not affected by *Klf5* deletion ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), ChIP-seq revealed that MyoD binding was markedly decreased in *Klf5* knockout cells compared to the GFP-targeted control cells on 3 day post-differentiation, as exemplified with *Myod1, Myog, Myl4* and *Mybph* ([Figure 6A and B](#fig6){ref-type="fig"}). This decrease in MyoD binding after *Klf5* deletion was similarly observed in another set of MyoD ChIP-seqs performed independently ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). The impaired recruitment of MyoD to the regulatory region of myogenic genes was further confirmed by ChIP-qPCR ([Figure 6C](#fig6){ref-type="fig"}). These results suggest that Klf5 plays a significant role in the recruitment of MyoD to target genes.10.7554/eLife.17462.016Figure 6.MyoD function is inhibited in *Klf5*-null C2C12 myoblasts.(**A**) UCSC genome browser images illustrating normalized tag counts for MyoD at *Myod1, Myog, Myl4* and *Mybph* gene loci in GFP-targeted control (orange) or *Klf5*-null (red) C2C12 myotubes differentiated for 3 days. (**B**) Distribution of MyoD tag densities in the vicinity of MyoD-bound enhancers in the GFP-targeted control or *Klf5*-null C2C12 myotubes differentiated for 3 days. (**C**) Comparison of MyoD recruitment at E-box containing enhancers of the *Myog, Mybph, Myom2* and *Myl4* gene loci in the GFP-targeted control and *Klf5* null C2C12 myotubes differentiated for 3 days. Data represent means ± SEM. (\*\*p\<0.01, \*\*\*p\<0.001, n = 3, biological replicates).**DOI:** [http://dx.doi.org/10.7554/eLife.17462.016](10.7554/eLife.17462.016)10.7554/eLife.17462.017Figure 6---figure supplement 1.Levels of MyoD and Mef2 protein were not altered by Klf5 deletion.Levels of MyoD, Mef2, Klf5 and Myog protein were analyzed by Western blotting using GFP-targeted control or *Klf5* knockout myoblasts differentiated for 5 days. Representative data from four individual experiments are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.017](10.7554/eLife.17462.017)10.7554/eLife.17462.018Figure 6---figure supplement 2.MyoD function is inhibited in *Klf5*-null C2C12 myoblasts -analysis in the another set of control and *Klf5*-null cells.(**A**) UCSC genome browser images illustrating normalized tag counts for MyoD at *Myog, Myl4, Mybph* and *Myod1* gene loci in GFP-targeted control or *Klf5*-null C2C12 myotubes differentiated for 3 days. (**B**) Distribution of MyoD tag densities in the vicinity of MyoD-bound enhancers in GFP-targeted control or *Klf5*-null C2C12 myotubes differentiated for 3 days.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.018](10.7554/eLife.17462.018)

Klf5 is required for satellite cell differentiation {#s2-7}
---------------------------------------------------

To further test the requirement for Klf5 in SC differentiation, SCs were isolated from the EDL muscle of *Pax7^CE/+^;Klf5^flox/flox^ *and control mice. Those SCs were cultured in growth medium for 3 days, then treated with 4OH-Tmx for 2 days to induce *Klf5* deletion by Cre-ER. In 4OH-Tmx treated *Pax7^CE/+^;Klf5^flox/flox^*SCs, Klf5 protein was undetectable. In these Klf5 knockout cells, myogenin protein was markedly reduced as compared to that in control *Pax7^CE/+^;Klf5^flox/flox^*SCs without 4OH-Tmx treatment ([Figure 7A](#fig7){ref-type="fig"}). In addition, mRNA expression levels of *Klf5* target genes exemplified by *Myog, Mybph* and *Myom2* were significantly decreased in those cells ([Figure 7B](#fig7){ref-type="fig"}). Collectively, these results indicate that Klf5 is indispensable for differentiation of primary SCs as well as C2C12 cells.10.7554/eLife.17462.019Figure 7.Klf5 is required for satellite cell differentiation.(**A**) Isolated SCs from Klf5 knockout mice (*Pax7^CE/+^;Klf5^flox/flox^*) were cultured in the presence or absence of 4OH-Tmx in growth medium for 2 days. Purified protein derived from primary myotubes differentiated for 3 days were analyzed by western blotting. Representative blots from three individual experiments are shown. (**B**) Relative mRNA expression of *Myog Myl4 and Myom2* in SCs differentiated for 3 days. Data represent means ± SEM (\*\*p\<0.01). Representative data from three individual experiments are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.019](10.7554/eLife.17462.019)

Discussion {#s3}
==========

Several pieces of evidence gathered in this study clarify the essential role of Klf5 in the control of adult skeletal muscle regeneration. First, although expression of Klf5 protein remained low in Pax7^+^ quiescent and activated SCs, Klf5 was significantly induced in myoblasts differentiating after skeletal muscle injury ([Figure 1](#fig1){ref-type="fig"}). Second, SC-specific deletion of *Klf5* markedly impaired muscle regeneration after injury due to a failure of differentiation ([Figure 2](#fig2){ref-type="fig"}), which confirmed the pivotal involvement of Klf5 in muscle regeneration *in vivo*. Third, suppressed differentiation into myotubes was observed in *Klf5*-null C2C12 myoblasts ([Figure 3](#fig3){ref-type="fig"}), after specific *Klf5* knockdown *in vitro* ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) and SCs from Klf5 KO mice ([Figure 7](#fig7){ref-type="fig"}). Fourth, inhibition of Klf5 affected transcriptional regulation of muscle-related genes by MRFs, including MyoD and myogenin ([Figures 4](#fig4){ref-type="fig"}--[6](#fig6){ref-type="fig"}). Collectively, these observations indicate that Klf5 is an essential component of the transcriptional regulatory network governing muscle differentiation and regeneration.

The molecular mechanism underlying muscle regeneration recapitulates many aspects of the process of muscle development. In particular, many of the transcription factors that control embryonic myogenesis also contribute to adult regenerative myogenesis. When a muscle is injured, hepatocyte growth factor (HGF), released from the basal lamina of the injured muscle triggers SC activation ([@bib48]). The activated SCs migrate and rapidly proliferate to give rise to Pax7^+^Myf5^+^ cells, which activate the MRF cascade ([@bib10]; [@bib25]). Our present results indicate that Klf5 is induced in myoblast-committed, non-dividing Pax7^low^MyoD^+^ SCs after they are triggered to differentiate into myocytes. Likewise, *Klf5* mRNA remained low in C2C12 myoblasts and SCs cultured in growth media. *Klf5* is greatly upregulated only after switching to differentiation media ([Figure 1C](#fig1){ref-type="fig"}, [Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). In differentiating myoblasts Klf5 is required for expression of *Myog* and muscle-specific genes. Given that Klf5 enhances binding of MyoD to its target sites, these findings collectively suggest that Klf5 is an important regulator that links the early specification program driven by MyoD and Myf5 to the late myotube formation and maturation program driven by myogenin and Mrf4.

To further elucidate the regulatory function of Klf5 in myogenesis, it will be important to determine how Klf5 expression is induced during myocyte differentiation and regeneration. Klf5 is reportedly induced in response to external/endogenous stimuli through various signaling cascades, including p38MAPK ([@bib31]; [@bib34]), ERK1/2 ([@bib24]) and IL-1β/HIF-1α ([@bib30]). We previously showed that the p38MAPK pathway controls upregulation of Klf5 in response to angiotensin II in smooth muscle cells ([@bib34]). The p38MAPK pathway is activated immediately after the onset of myogenic differentiation and muscle regeneration ([@bib7]), and is essential for myoblast differentiation ([@bib18]). Moreover, genome-wide transcriptome analysis of SCs with muscle-specific p38α deletion or C2C12 cells treated with a p38 MAPK inhibitor revealed that p38α is responsible for induction of Klf5 during myoblast differentiation ([@bib42]). Interestingly, that study also showed that inhibiting p38 signaling does not affect expression of MyoD. It therefore seems likely that Klf5 is an essential component of the transcriptional machinery activated by p38 MAPK during myogenic differentiation. A previous study showed that Klf2 and Klf4 are induced by ERK5 signaling and contribute to muscle cell fusion ([@bib46]). Microarray analyses in that study indicate that Klf5 expression is not affected by inhibition of ERK5 signaling (GSE25827). This is in agreement with our previous observations that Klf5 expression was unaffected by a MEK inhibitor in smooth muscle cells ([@bib34]). These findings indicate that members of Krüppel-like factor family differentially contribute to different processes during muscle differentiation and maturation. That said, it is possible that the loss of Klf5 is compensated by other Klf members, as we observed modest changes in the expression of other Klfs in Klf5-deficient C2C12 cells ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Future studies of possible cooperation and competition among Klf members will be important for elucidating their functional roles in muscle biology. In addition, we found that exogenous Klf5 increased the level of eMyHC in Klf5-deleted C2C12 myotubes, but did not fully recapitulate the normal level of eMyHC expression ([Figure 3](#fig3){ref-type="fig"}). This insufficient rescue may reflect differences between endogenous and exogenous Klf5, including the levels and timing of Klf5 expression. In the control cells, for example, Klf5 was transiently upregulated early during differentiation, but this temporal regulation of Klf5 was lost in cells in which exogenous Klf5 was stably expressed. Future studies will also need to address the temporal regulation of Klf members during muscle differentiation and regeneration.

Our ChIP-seq results indicate that deletion of Klf5 impairs recruitment of MyoD. This demonstrates that Klf5 is required for formation of MyoD-containing transcriptional regulatory complexes in at least a subset of the MyoD cistrome ([Figure 6](#fig6){ref-type="fig"}). Recent studies have identified several transcription factors that interact with MyoD. For instance, Runx1 is induced in response to muscle injury and acts cooperatively with MyoD and c-Jun to regulate muscle regeneration ([@bib49]). TEAD4 is another factor reportedly recruited and bound to the locus also occupied by MyoD during the course of myogenic differentiation ([@bib2]). Inhibition of Runx1 or TEAD4 suppresses myogenic differentiation and regeneration, suggesting those two transcription factors, together with MyoD, are necessary to drive muscle regeneration. Of interest, we observed the sequence motif bound by Runx to rank 4th and the MCAT motif bound by TEAD4 to rank 6th among the de novo motifs identified in regions bound by Klf5 in myotubes differentiated for 5 days ([Figure 5F](#fig5){ref-type="fig"} and data not shown). These data suggest that Klf5 promotes myogenic differentiation by interacting with multiple transcription factors, including MyoD, Mef2, Runx1 and TEAD4. It is likely these transcription factors are differentially regulated in response to different environmental cues and/or endogenous signaling. Accordingly, the interplay between these multiple factors would enable spatiotemporal regulation and fine tuning of muscle-related gene expression. It would be important to further clarify the logic of transcriptional regulation by these multiple transcription factors. It would also be worth noting that there appears to be a complex cross-regulation of the expression of these factors. For instance, in addition to myogenin, Klf5 appears to regulate TEAD4 because there were Klf5 binding peaks in the vicinity of the genes in our ChIP-seq, and *Klf5* knockdown reduced TEAD4 levels (data not shown). In addition, based on a published microarray analysis of effects of an individual Mef2 isoform (GSE63798) ([@bib14]) and our results from smooth muscle cells ([@bib34]), it appears Klf5 is regulated by Mef2A. This reciprocal regulation of Klf5 and other myogenic transcription factors support the notion that Klf5 is a component of an intricate transcription factor network that regulates muscle differentiation and regeneration.

In addition to MyoD and Mef2 identified in the present study, Klf5 has been shown to interact with various other transcription factors and cofactors. For instance we showed that Klf5 interacts with C/EBΒβ and δ to regulate adipocyte differentiation ([@bib32]), interacts with PPARδ to regulate lipid metabolic genes ([@bib33]), and interacts with C/EBPα to control the response to renal injury ([@bib17]). Klf5 also interacts with unliganded RAR/RXR to induce phenotypic modulation of vascular smooth muscle cells ([@bib16]). By taking advantage of this mechanism, we showed that an RAR agonist can inhibit induction of Klf5 target genes, thereby suppressing smooth muscle cell proliferation and neointima formation. We may therefore be able to manipulate the muscle regeneration program by altering the activity of Klf5 through its interacting partners. In sum, our results provide evidence that during skeletal muscle regeneration and myoblast differentiation, Klf5 regulates the expression of late muscle-specific genes in concert with MyoD and Mef2. This finding suggests that it will be of interest to investigate this pathway further with respect to the control of muscle regeneration. It would also be interesting to know whether Klf5-mediated pathways are involved in such pathological conditions as sarcopenia.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Klf5^flox/flox^* mice ([@bib47]) were crossed with *Pax7^CreERT2/+^* mice (Abbreviated *Pax7^CE/+^* \[[@bib26]\]) to generate *Pax7^CE/+^;Klf5^flox/flox^* mice. All mice used in this study had a C57BL/6J genetic background, were between 8--12 weeks old and had age-matched littermate controls. Animal experimentation was approved by the Experimental Animal Care and Use Committee of Tokyo Medical and Dental University (approval numbers 2013-027C12 and 0170280C).

Muscle regeneration {#s4-2}
-------------------

Tamoxifen (Sigma-Aldrich, St. Louis, MO) was dissolved in corn oil (Nakarai, Tokyo, Japan) to a concentration of 20 mg/ml. Eight- to twelve-week-old *Klf5^flox/flox^* and *Pax7^CE/+^;Klf5^flox/flox^* mice were intraperitoneally injected with 100 µl of tamoxifen solution daily for 5 days prior to induction of muscle injury. To induce muscle regeneration, 100 µl of 10 mM cardiotoxin (CTX: Sigma-Aldrich) were injected intramuscularly into the tibialis anterior (TA) muscle of anesthetized mice using a 29G syringe. Regenerating muscles were isolated 4, 7 and 28 days after CTX injection, immediately frozen in cooled isopentane in liquid nitrogen, and stored at −80°C before being cryosectioned. To analyze the distribution of fiber diameters, at least three sections from each of four *Pax7^CE/+^;Klf5^flox/flox^* mice and four *Pax7^+/+^;Klf5^flox/flox^* (control) mice were examined. Immunofluorescent images of laminin were acquired, after which the area surrounded by the laminin signal in each cross-section was quantified using Olympus cellSense Digital Imaging software. In each mouse, the diameters of 1000 (for CTX day 7) or 500 (for CTX day 28) regenerating fibers that had centrally located myonuclei were determined.

Satellite cell isolation, culture conditions and transfection {#s4-3}
-------------------------------------------------------------

Extensor digitorum longus (EDL) muscles were isolated from wild type C57/BL6 males and digested in type I collagenase (Worthington Biochemical Corp., Freehold, NJ). SCs were obtained from isolated myofibers by trypsinization in 0.125% trypsin-EDTA solution for 10 min at 37˚C with 5% CO~2~. SCs were cultured in GlutaMax DMEM (Life Technologies, Grand Island, NY) supplemented with 20% fetal bovine serum (FBS: Hyclone, Thermo scientific, Hudson, NH), 1% chick embryo extract (US Biological, Salem, MA), 10 ng/ml basic fibroblast growth factor (Cell Signaling Technology, Beverly, MA), and 1% penicillin-streptomycin at 37˚C with 5% CO~2~. Myogenic differentiation was induced in GlutaMax DMEM supplemented with 2% horse serum and 1% penicillin-streptomycin at 37˚C with 5% CO~2~.

To assess satellite cells obtained from *Pax7^CE/+^;Klf5^flox/flox^* mice, the cells were treated with 1 µM 4-hydroxytamoxifen (4OH-Tmx; Sigma-Aldrich, H7904) or vehicle 3 days after isolation, then grown in growth medium for another 2 days.

C2C12 mouse myoblasts (RRID:[CVCL_0188](https://scicrunch.org/resolver/CVCL_0188)) were purchased from the ATCC (ATCC \#CRL-1772, passage number 6--8, Rockville, MD). The identity was not authenticated by our hands. Cells were free from mycoplasma contamination confirmed by monthly tests for mycoplasma. Cells were cultured in DMEM (Nakarai) containing 10% FBS and 1% penicillin-streptomycin at sub-confluent densities. C2C12 cells were differentiated into myotubes by replacing growth medium with medium containing 2% horse serum with antibiotics (differentiation medium, DM). To knock down Klf5 in C2C12 cells, siKlf5 (Thermo scientific, Dharmacon, siRNA-SMARTpool, M-062477-01-0005) treatment was carried out using RNAiMAX (Life Technologies) according to the manufacturer's instructions. Each experiments were biologically replicated at least three times.

Generation of *Klf5* knockout C2C12 cells {#s4-4}
-----------------------------------------

*Klf5* gene was engineered as described previously ([@bib38]). Briefly, a plasmid vector containing clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 endonuclease coupled with paired guide RNAs flanking the mouse *Klf5* gene was transiently transfected into C2C12 cells. Deletion of targeted loci was confirmed by sequencing. Cells transfected with a plasmid vector carrying CRISPR-Cas9 endonuclease coupled with paired guide RNAs flanking the GFP sequence were used as a control (Abbreviated GFP-targeted control).

Immunofluorescent staining {#s4-5}
--------------------------

Cryosections (10 µm thickness) were fixed in 4% paraformaldehyde (PFA)/PBS for 10 min at room temperature. For antigen retrieval, the sections were incubated in 0.01 M citric acid solution (pH 6.0) for 10 min at 80°C. The sections were then permeabilized in methanol for 6 min at −20°C. Cultured cells were also fixed in 4% PFA/PBS for 10 min at room temperature and permeabilized in 0.5% TritonX-100/PBS solution for 5 min at room temperature after washing 3 times. The sections and cells were then blocked in 5% BSA/PBS blocking solution, after which primary antibodies prepared in blocking solution were added and incubated at 4°C overnight. This was followed by 3 washes in PBS and incubation with Alexa fluor-conjugated antibodies (Life Technologies) in blocking solution for 1 hr at room temperature. After another 3 washes in PBS, the sections were counterstained with Hoechst 33342 solution at room temperature for 3 min. The slides were mounted with a coverslip and Fluoromount-G (SouthernBiotech, Birmingham, AL). Immunofluorescent signals from stained sections and cells were captured using a LSM710 confocal imaging system (Carl Zeiss, Inc., Oberkochen, Germany) or OLYMPUS IX73 fluorescence inverted fluorescence microscope with an Olympus DP80 camera and Olympus cellSense Digital Imaging software (Tokyo, Japan).

Retroviral infection and plasmid vectors {#s4-6}
----------------------------------------

Murine *Klf5* cDNA was cloned into the retroviral backbone pMX-GFP (Cell Biolabs, San Diego, CA) to produce pMX-Klf5-GFP (RV-Klf5), after which the retroviruses were packaged into the Platinum-E (PLAT-E) Retroviral Packaging Cell Line (Cell Biolabs) according to the manufacturer's instructions. Retroviral infection was accomplished at 37°C overnight using PLAT-E supernatant supplemented with 4 µg/ml polybrene.

Immunoprecipitation {#s4-7}
-------------------

Cellular protein (600 µg) from differentiated C2C12 myotubes was mixed with 2 µg of anti-MyoD, anti-Klf5 or anti-Mef2 antibody and incubated overnight at 4°C. Twenty µl of protein G Dynabeads (1001D; Life Technologies) were then added to each sample and incubated for 1 hr at 4°C. After the incubation, the samples were washed 6 times with wash buffer (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDAT, 1 mM DTT, 0.5% NP40 and 0.5% TritonX-100), resuspended in SDS sample buffer and heated at 98°C for 5 min prior to electrophoresis. Each experiments were biologically replicated at least three times.

Immunoblotting {#s4-8}
--------------

Proteins were quantified using a BCA Protein assay kit (Pierce, Rockford, IL) following the manufacturer's protocol. Thirty μg of total protein were separated by 10% SDS-PAGE and transferred onto PVDF Immobilon-P membranes (Millipore, Billerica, MA). Western blotting was performed using ECL Prime detection reagent (GE, Waukesha, WI) according to the manufacturer's instructions. Each experiments were biologically replicated at least three times.

Real-time PCR analysis {#s4-9}
----------------------

Total RNA was isolated from cultured cells using an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer\'s protocol. RNA or ChIP-DNA were analyzed using real-time PCR with a KAPA SYBR Fast qPCR Kit (Kapa Biosystems, Woburn, MA). The primers for qPCR are listed in Table 2. Each experiments were biologically replicated at least three times.

Luciferase assay {#s4-10}
----------------

Murine *Klf5* (Genbank accession number: NM_009769) was sub-cloned into p3xFlag-CMV-7.1 vector. The Myog-Luciferase vector was kindly provided by Dr. T. Sato (Kyoto Prefectural University of Medicine, unpublished). The *Myod1* expression vector was a gift of Dr. P. Maire (Institute Cochin) ([@bib40]). The *Mef2d* expression vector was kindly provided by Dr. E. Olson (University of Texas Southwestern Medical Center). The 293T cells were transfected with a CMV-Renilla luciferase control reporter plasmid along with Myog-Luciferase, *Klf5, Myod1* and *Mef2d* expression plasmids. The total amount of plasmid DNA was kept constant using p3xFlag-CMV-7.1 empty vector. Forty-eight hours after transfection, the cells were lysed in Passive Lysis Buffer (Promega) and shaken for 15 min. The lysates were used for measurement of firefly and Renilla luciferase activities using EnSpire (PerkinElmer, Waltham, MA), after which the firefly luciferase activity was normalized to the Renilla luciferase activity.

Library preparation and RNA-seq {#s4-11}
-------------------------------

PolyA-tagged RNA was pulled down from total RNA using oligo-dT magnetic beads. RNA-seq libraries were multiplexed and prepared according to the manufacturer\'s protocol (NEB cat\#E7530, Ipswich, MA). Libraries were paired-end sequenced on a HiSeq2500 sequencer (Illumina, San Diego, CA). Reads were aligned to the mm9 genome using the default parameter for RNA-star. Aligned read files were analyzed with HOMER (<http://homer.salk.edu/homer/>) to calculate RPKM from the gene bodies of RefSeq genes and perform motif analysis. Reads counts were normalized using DESeq2 ([@bib28]).

Chromatin immunoprecipitation (ChIP) {#s4-12}
------------------------------------

Undifferentiated C2C12 myoblasts and myotubes differentiated for 2 or 5 days were used for Klf5 ChIP. For MyoD ChIP in CRISPR-engineered cells, cells differentiated for 3 days were used. Cells were fixed in 1% formaldehyde for 10 min at room temperature. The reactions were stopped by adding glycine to a final concentration of 0.125 M and incubating for 10 min at room temperature. After washing with PBS, the cell pellet was lysed in ice-cold Cell Lysis Buffer, incubated on ice for 10--20 min and centrifuged at 3000 rpm for 5 min at 4°C. The pellet was further lysed in ice-cold RIPA buffer and incubated on ice for 10 min. The resultant cell lysate was sonicated using an ultrasonicator (output 50, 30-s pulses then 1-min pause × 13 times; UD-100: TOMY Seiko, Tokyo, Japan). The chromatin was then pre-cleared by incubating with Sepharose CL-4B (Sigma- Aldrich) for 2 hr at 4°C with constant rotation. After centrifugation, anti-MyoD or anti-Klf5 antibody was added and rotated overnight at 4°C. Protein A-Sepharose 4B fast flow (BD) was then added and incubated for 1 hr at 4°C with constant rotation. Thereafter, the beads were washed 4 times with RIPA buffer, 6 times with LiCl buffer and 3 times with TE buffer, then eluted with 2% SDS solution. After reverse cross-linking at 65°C overnight, the chromatin immunoprecipitate and Input were treated with RNase (37°C, 1 hr) and Proteinase K (42°C, 1 hr). The recovered chromatin was purified using a MiniElute PCR Purification kit (Qiagen) and used for real-time PCR analysis.

Library preparation and ChIP-Seq {#s4-13}
--------------------------------

Sequencing libraries were prepared from collected DNA by using NEB next Ultra DNA library prep kit for Illumina according to the manufacturer\'s protocol (NEB, Ipswich, MA). Libraries were PCR-amplified for 12--15 cycles, size selected by gel extraction and sequenced on a Hi-Seq 1500 (Illumina) for 51 cycles.

ChIP-seq analysis {#s4-14}
-----------------

ChIP-seq data for MyoD and Mef2D binding in C2C12 cells (SRA010854 and SRP017715) were downloaded from NCBI. Reads were mapped to the mm9 genome using STAR ([@bib12]). Peak calling and annotation was performed using HOMER version 4 ([@bib21]) for MyoD and Klf5, and using MACS2 ([@bib53]) for Mef2D. Peaks that overlapped blacklisted regions ([@bib9]) or simple repeat regions were removed. Homer-identified MyoD and Klf5 peaks with scores ≥20 were considered high confidence binding sites and used for further analyses, except for detection of MyoD peaks in the vicinity of Klf5 peaks in [Figure 5](#fig5){ref-type="fig"}. To make a set of potential MyoD-regulated genes, RefSeq genes that contained MyoD peaks within a region −1500 bp from TSS to +1500 bp from TTS were first chosen. Then genes whose normalized counts were increased ≥2-fold in C2C12 myotubes relative to those in myoblasts were selected. The resultant MyoD target gene set contained 753 RefSeq genes. This gene set was highly enriched in GO terms related to muscle differentiation. All RNA-seq and ChIP-seq data are available in the GEO under the accession number GSE80812. To identify enriched motifs in ChIP-seq peaks, we used Homer's findMotifsGenome.pl software ([@bib21]).

Statistical analysis {#s4-15}
--------------------

Sample sizes were not based on power calculations. No animals were excluded from analyses. Comparisons between two groups were analyzed using two-tailed Student's *t*-test. Differences among more than two groups were analyzed using one-way ANOVA followed by Tukey-Kramer post-hoc tests. Values of p\<0.05 were considered statistically significant, except in analyses involving RNA-seq and ChIP-seq. All data are means ± SEM.

Additional information {#s4-16}
----------------------

Details of antibodies and sequences for qPCR are described in [Supplementary file 1](#SD2-data){ref-type="supplementary-material"}.
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Major datasets {#s7}
--------------

The following dataset was generated:

Yumiko Oishi,2016,Klf5 regulates muscle differentiation via directly targeted muscle-specific genes in cooperation with MyoD,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80812>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE80812)

The following previously published datasets were used:

Cao Y,Yao Z,2010,Genome-wide analysis of gene expression during differentiation in C2C12 cells,<https://www.ncbi.nlm.nih.gov/sra?term=SRA010854>,Publicly available at the NCBI Sequence Read Archive (accession no: SRA010854)

Sebastian S,Dilworth FJ,2013,Alternate exon switching establishes a tissue-specific transcription factor to mediate temporal activation of gene expression during differentiation,<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43223>,Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE43223)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Klf5 regulates muscle differentiation by directly targeting muscle-specific genes in cooperation with MyoD\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Janet Rossant as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Mukesh Jain (Reviewer \#1); Atsushi Asakura (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

In this study Hayashi and colleagues report the novel finding that KLF5, a zinc-finger transcription factor, regulates myogenesis by controlling muscle specific gene expression in cooperation with MyoD. The experimental work is well executed and the manuscript is clearly written. However a number of points need to be addressed, some of which require additional experimentation.

1\) The authors should show that KLF5 is an active transcription factor for myogenesis when associated with MyoD and MEF2. For this, the authors should examine a reporter assay such as Myogenin-promoter-luciferase which is known to be regulated by MyoD and MEF2. Co-transfection experiments should be done for MyoG-Luc with Klf5, MyoD and MEF2.

2\) The relationships between MyoD occupancy, KLF5 occupancy and gene expression changes are not well defined. For example, it appears that a substantial fraction of MyoD-regulated genes have higher expression with KLF5 reduction. Is MyoD binding increased at these genes, which are essentially ignored in the text? Moreover, the relationship between altered MyoD binding and changes in gene expression with KLF5 reduction are not fully delineated. Is reduced gene expression always associated with reduced MyoD binding?

The following comments (3-5) are related to this point:

3\) In [Figure 4](#fig4){ref-type="fig"}, why use siRNA instead of the CRISPR lines, which are complete knockouts? The set of genes that are impacted by Klf5 deletion appears small to moderate in size, not \"global\" as stated in the text. Is there some defining feature of this set and how were the genes with increased expression with KLF5 reduction different than those with decreased expression? The increased expression set should be addressed here and elsewhere.

4\) Given that the authors are using a published MyoD dataset in which a similar motif (Sp1) was defined, some comparison/explanation of the motif analysis would appear to be in order ([Figure 5](#fig5){ref-type="fig"}). In addition, the paper from which the published ChIP-seq data is extracted has various timepoints and it is not clear which time point is shown -- certainly not a later timepoint, which is confusing, as the main point is that KLF5 goes up and influences MyoD over time.

5\) What is the scale for relative read number in the ChIP-seq shown in [Figure 6](#fig6){ref-type="fig"}? How does the quality (and the identified MyoD binding sites) compare with the published dataset used earlier? How many days into differentiation is this? Why is MyoD binding globally down whereas only a subset of MyoD targets exhibit disrupted regulation in the RNA-seq data shown in [Figure 4](#fig4){ref-type="fig"}? What is the overlap between reduced MyoD binding sites in the Klf5 KO cells and the KLF5 ChIP-seq data sets? Could the two MyoD ChIPs (i.e. WT and Klf5 KO) be of different quality rather than reflective of biological differences?

Additional points:

6\) Overall knockout and knockdown experiments were done with C2C12 cells. Please check that similar results are obtained using Klf5 KO primary myoblasts.

7\) For completeness the authors should verify that MEF2 protein is also unaffected in the setting of Klf5 deletion.

8\) The presence of other KLF family members might partially compensate for the differentiation defect of Klf5 KO cells. Please show data on the expression of other Klf gene family members during myogenic differentiation or at least discuss this further citing existing data. The authors mention KLF2/4 in the context of muscle fusion but there are others that have been linked to skeletal muscle biology and it is important to provide this background.

9\) The murine pictures ([Figure 1](#fig1){ref-type="fig"}) do not really appear to support the conclusions that are stated in the text and in the legend. The change in Klf5 expression does not appear to be very dramatic, nor is the small set of images shown without quantification sufficient to support the notion that Klf5 expression specifically increases with regeneration and concomitant with myogenin expression *in vivo*. More quantitation is necessary. The C2C12 data are much more clear.

10\) In relation to [Figure 2](#fig2){ref-type="fig"}, It is stated in the text that no effect of tamoxifen is seen until 28 days without injury. It would appear critical to show the effect of losing KLF5 on normal muscle morphology at this time point. There is also no methodology described for how muscle size was quantified in terms of mouse number, sections examined etc., and there are no SDs shown on the graph. Given the heterogeneity in mouse injury from experiment to experiment, \"n of 3\" is a limited number to conclude that \"representative data\" are shown. In addition, no data are shown to verify that injury was similar at early time points in a set of control and Klf5 KO mice..

11\) The level of MHC expression by immunoblot ([Figure 3](#fig3){ref-type="fig"}) seems very low in the normal cells in comparison to the robust immunostaining. It is also surprising that no MHC is seen in the Klf5 KO cells, given the obvious (albeit reduced) MHC in the KO cells with immunostaining. This raises a concern about how representative the depicted blots are of MHC expression, a concern that is furthered by the clear expression of MHC in the KO cells on 3E. In addition, although the rescue of MHC expression by exogenous KLF5 in the CRISPR line is clear, it is also poor and incomplete and this should at least be discussed.

10.7554/eLife.17462.032

Author response

\[...\]

*1) The authors should show that KLF5 is an active transcription factor for myogenesis when associated with MyoD and MEF2. For this, the authors should examine a reporter assay such as Myogenin-promoter-luciferase which is known to be regulated by MyoD and MEF2. Co-transfection experiments should be done for MyoG-Luc with Klf5, MyoD and MEF2.*

We greatly appreciate the reviewer's valuable suggestions. We agree there is a need for functional assays. We have performed reporter assays by transfecting a *Myogenin* promoter-luciferase construct along with Klf5, MyoD and Mef2D expression plasmids, as suggested by the reviewer. This reporter construct is composed of \~3.8 kb of the myogenin 5'-flanking region, which contains the region bound by Klf5, MyoD and Mef2D, as indicated in [Figure 5A](#fig5){ref-type="fig"}. The reporter assay showed that the *Myog* promoter was activated by Klf5 alone, and addition of MyD and Mef2D further activated the promoter, suggesting activating cooperation among Klf5, MyoD and Mef2D. This result is in agreement with the co-association of the three transcription factors to the *Myog* promoter ([Figure 5H](#fig5){ref-type="fig"}). The observations that *Klf5* knockdown reduced expression of many MyoD-target genes ([Figure 4D](#fig4){ref-type="fig"}) and that MyoD association to the target sites was reduced by *Klf5* knockout ([Figure 6A-B](#fig6){ref-type="fig"}) suggest Klf5 mainly acts as a positive regulator of MyoD-driven gene expression and myogenesis.

*2) The relationships between MyoD occupancy, KLF5 occupancy and gene expression changes are not well defined. For example, it appears that a substantial fraction of MyoD-regulated genes have higher expression with KLF5 reduction. Is MyoD binding increased at these genes, which are essentially ignored in the text? Moreover, the relationship between altered MyoD binding and changes in gene expression with KLF5 reduction are not fully delineated. Is reduced gene expression always associated with reduced MyoD binding?*

As pointed out, expression of a number of genes was increased in *Klf5* knockdown cells on day 3. Among the 753 MyoD-target genes depicted as red points in [Figure 4D](#fig4){ref-type="fig"}, expression of 55 genes was increased by \>1.5-fold. As suggested, we analyzed MyoD binding to the MyoD binding sites within +/-1.5 kb of the genes that were upregulated or downregulated by *Klf5* knockdown. As shown in [Author response image 1A](#fig8){ref-type="fig"}, even in regions near the upregulated MyoD-target genes, MyoD density was decreased in *Klf5* knockout cells.

The precise mechanism by which expression of the genes upregulated by *Klf5* deletion was increased despite the reduced MyoD binding is not immediately clear. It is possible that other MRFs, such as Myf5, compensate for the reduced association of MyoD, as recently reported (Conerly M., Tapscott S. et al. Dev Cell36: 375, 2016). It is also possible that MyoD binding is dispensable for the activity of the enhancers. Another possibility is that MyoD negatively regulates the activity of enhancers. More importantly, proximity of an enhancer to a gene does not necessarily indicate a functional link between them.

As suggested, we analyzed MyoD binding to sites near all genes (not limited to the MyoD target genes) whose expression levels were decreased by \>1.5 fold in *Klf5* knockdown cells as compared with control cells on day 3. As shown by the red dots in the MA plot of MyoD counts at MyoD sites ([Author response image 1B](#fig8){ref-type="fig"}), binding was reduced at the majority of MyoD peaks near the downregulated genes, though a minor fraction of sites showed increased MyoD binding.

Because proximity of an enhancer to a gene does not necessarily indicate a functional link between them, it is not trivial to identify enhancers functionally linked to genes. Accordingly, we further analyzed the relationship between Klf5 and MyoD binding regardless the distance to genes. A new heatmap for Klf5, MyoD and Mef2D binding around the center of the top 1000 Klf5 binding peaks ([Figure 5B](#fig5){ref-type="fig"}) show that at the Klf5 peaks in myotubes (day 5) that had significant nearby MyoD peaks, Klf5 binding were increased during differentiation (day 0 to 5), which is evident in histograms of Klf5 binding ([Figure 5C](#fig5){ref-type="fig"}). This co-association of MyoD and Klf5 is also shown by the histogram of Klf5 binding around the center of the MyoD peaks, in which Klf5 binding was increased as differentiation progressed ([Figure 5B](#fig5){ref-type="fig"}) In sharp contrast, a smaller fraction of top 1000 Klf5 peaks in myoblasts (day 0) had nearby MyoD peaks, and Klf5 binding was unchanged or decreased during differentiation ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). These results suggest there are two subsets of Klf5 binding sites: those with increasing Klf5 binding during differentiation and those with decreasing Klf5 binding. The former is more strongly related to adjacent MyoD binding, while the latter is less associated with MyoD binding. Because of cooperation between Klf5 and MyoD during differentiation, *Klf5* deletion might have a stronger impact on the MyoD binding sites associated with increasing Klf5 binding. Indeed, *Klf5* deletion markedly reduced MyoD binding at the MyoD binding sites with increased Klf5 binding on day 5 as compared with that on day 0 (\>4-fold increased Klf5 counts within 400 bp around the center of MyoD binding peak), whereas *Klf5* deletion did not affect MyoD binding at the MyoD sites with decreased Klf5 binding (\>4-fold decreased Klf5 counts) (see [Author response image 1C](#fig8){ref-type="fig"}). These results demonstrate that *Klf5* deletion has a strong impact on the sites with increasing association with Klf5 and MyoD, and support the notion that Klf5 and MyoD cooperatively proceed during the muscle differentiation program. Though these analyses support our conclusions, extensive ChIP-seq and chromosome conformation capture analyses will be needed to further clarify relationships between enhancer activity and Klf5/MyoD binding, and enhancer activity and gene transcription. Moreover, the present study focuses on the Klf5's function in myogenesis and regeneration. Accordingly, while we have added heatmaps of Klf5, MyoD and Mef2D and briefly discussed the increasing co-association of Klf5 and MyoD in differentiation, we decided not to add the analyses shown in [Author response image 1](#fig8){ref-type="fig"}.10.7554/eLife.17462.021Author response image 1.(**A**) Histograms of MyoD tag densities around MyoD binding peaks proximal to MyoD target genes that were upregulated or downregulated (\>1.5-fold) by *Klf5* deletion. (**B**) MA plot of normalized tag counts at MyoD biding regions in *Klf5* knockout and control cells. MyoD binding regions proximal to genes whose expression was decreased (\>1.5-fold) in *Klf5* knockout cells as compared with control cells are shown as red dots. (**C**) Histograms of MyoD tag densities around MyoD binding peaks that had \>4-fold increase or decrease in counts nearby (400 bp) *Klf5* between day 0 and 5. MyoD densities in *Klf5* knockout and control mice are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.021](10.7554/eLife.17462.021)

*The following comments (3-5) are related to this point:*

*3) In [Figure 4](#fig4){ref-type="fig"}, why use siRNA instead of the CRISPR lines, which are complete knockouts? The set of genes that are impacted by Klf5 deletion appears small to moderate in size, not \"global\" as stated in the text. Is there some defining feature of this set and how were the genes with increased expression with KLF5 reduction different than those with decreased expression? The increased expression set should be addressed here and elsewhere.*

We chose to use cells transiently transfected with siRNA instead of the CRISPR lines because other transcription factors, including Klf family members, might compensate for the defect in *Klf5* in stable knockout cells, as pointed out in comment (8). We agree that the set of genes affected by *Klf5* deletion appears small to moderate in size. Our intention was to indicate that *Klf5* deletion had a wide impact on expression of genes related to myogenesis, because 1472 genes in the hallmark myogenesis gene set out of 12744 annotated transcripts were reduced \>1.5-fold in *Klf5* knockdown cells, and *Klf5* deletion severely affected myogenesis. However, we absolutely agree with the reviewer that the use of "globally" may cause unnecessary misunderstanding. Accordingly, we avoided the use of "globally" and revised the sentences accordingly.

As suggested we analyzed gene set enrichment in the genes upregulated by *Klf5* knockdown. The results indicate that no gene sets directly related to myogenesis was significantly enriched. This is presented in the revised manuscript and shown in [Figure 4---source data 1](#SD1-data){ref-type="supplementary-material"}.

*4) Given that the authors are using a published MyoD dataset in which a similar motif (Sp1) was defined, some comparison/explanation of the motif analysis would appear to be in order ([Figure 5](#fig5){ref-type="fig"}). In addition, the paper from which the published ChIP-seq data is extracted has various timepoints and it is not clear which time point is shown -- certainly not a later timepoint, which is confusing, as the main point is that KLF5 goes up and influences MyoD over time.*

We thank the reviewer for comments pointing out such important issues. The MyoD ChIP-seq dataset from a previously published paper (Cao et al. Dev Cell2010) used C2C12 cells differentiated into myotubes for 48 h. We chose it to analyze the co-association of MyoD and Klf5 in myotubes, because Klf5 was increasingly recruited to many MyoD-binding regions over the course of C2C12 differentiation (please see [Figure 5A-C](#fig5){ref-type="fig"}). This is now more clearly presented in the figure legend.

In the present study we used Homer (<http://homer.salk.edu/homer>) for de novomotif discovery. This program first assembles highly similar sequences as a single motif and then assigns the known motif that is most closely matched with the de novomotif. The rank 4 motif in [Figure 4G](#fig4){ref-type="fig"} most closely matched the KLF5 motif in Homer's motif database. As pointed out, Sp and KLF family transcription factors bind to similar GC-rich sites, though their optimal binding sequences differ (Genomics87:474-482, 2006). The earlier paper (Cao et al. Dev Cell. 2010) identified a high affinity Sp1 site with a "CCGCCC" core sequence. Our rank 4 motif is GGG(C/T)G(T/G)GGCC, which may include "CCGCCC", though the sequence better fits the known KLF binding consensus than the Sp1 motif. To better characterize the association of the Sp1 motif with MyoD binding sites, we analyzed appearance of the known Sp1 motif. The result indicates that the Sp1 motif is present in 4.9% of the MyoD-binding regions (*P*=1e-19). We added this result to [Figure 4G](#fig4){ref-type="fig"} and indicate the use of Homer's software in the Materials and methods. We have revised the section describing the results of the motif findings to better reflect the algorithm of Homer. We also clearly state that the identified Klf5 binding sequences may contain Sp1 binding sequences.

*5) What is the scale for relative read number in the ChIP-seq shown in [Figure 6](#fig6){ref-type="fig"}? How does the quality (and the identified MyoD binding sites) compare with the published dataset used earlier? How many days into differentiation is this? Why is MyoD binding globally down whereas only a subset of MyoD targets exhibit disrupted regulation in the RNA-seq data shown in [Figure 4](#fig4){ref-type="fig"}? What is the overlap between reduced MyoD binding sites in the Klf5 KO cells and the KLF5 ChIP-seq data sets? Could the two MyoD ChIPs (i.e. WT and Klf5 KO) be of different quality rather than reflective of biological differences?*

We apologize for the insufficient description of methods and experimental conditions. We performed MyoD ChIP-seq in *Klf5*-knockout C2C12 cells generated using the CRISPR-Cas9 method. As a control, we used C2C12 cells transfected with CRISPR-Cas9 endonuclease coupled with paired guide RNAs flanking the GFP sequence (GFP-targeted control). The cells were harvested 3 days after induction of differentiation for ChIP-seq analysis. We have expanded the experimental procedure section to address these issues (subsection "Klf5 is required for myoblast differentiation", second paragraph).

Because ChIP-seq of MyoD in *Klf5* knockout and control cell lines in the original manuscript had less than 10 million mapped reads (5,047,433 and 8,016,529 mapped reads, respectively), we repeated the sequencing to increase the sequence depth. Now the numbers of mapped reads are comparable with the previously published data (Cao Y. et al) used to identify MyoD binding regions. Still, the number of MyoD peaks (2,225) that were identified using the CRSPR-GFP-control cells, is smaller than the number of MyoD-binding peaks (12,769) identified using the published data. However, 86% of our MyoD peaks overlapped with the MyoD peaks in the published data.

Moreover, the heatmap for MyoD binding shows a strong similarity (please see Figure III). Clearly, our ChIP-seq reads are enriched at the MyoD peaks identified by the published MyoD ChIP-seq. However, the peak intensity was generally lower in our MyoD ChIP-seq than that in the published data, which appears to be one reason why our ChIP-seq identified only a subset of MyoD peaks. A number of technical differences are likely to affect the quality of ChIP-seq. For instance, the antibody we used was one commercially available from Santa Cruz and recognized the full length of mouse MyoD. By contrast, Cao et al. used three antibodies developed in their lab that recognized amino acids 160-307, 60-219 and 3-318 of mouse MyoD (Cao Y et al. Dev Cell18: 662, Tapscott, SJ et al. Science242: 405-11, 1988). This difference in antibodies likely contributes to the relatively low peak intensity in our ChIP-seq. That said, the very high overlap (86%) between our MyoD peaks and the MyoD peaks in the published data, and the very similar read distributions in the heatmap, indicate that the two antibody sets largely recognize the same regions.

Table

Mapped readsMyoD ChIP-seq (C2C12 cells differentiated into myotube for 48 h, Cao et al. Dev Cell2010)8,797,472MyoD ChIP-seq in CRISPR-GFP-control C2C12 cells differentiated into myotube for 72 h13,628,080MyoD ChIP-seq in CRSPR-KLF5 knockout C2C12 cells differentiated into myotube for 72 h15,801,588

To further confirm the observation that MyoD recruitment was impaired in the absence of *Klf5*, we performed an independent MyoD ChIP-seq experiment using another set of cells as a biological replicate. The observation that the lack of *Klf5* reduces MyoD binding was reproduced in the independent experiment, verifying that impaired MyoD recruitment reflects biological differences, but not a difference in the quality of MyoD ChIPs in control and *Klf5* knockout cells. These results are now presented in [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}.

Among 735 MyoD target genes, the expression levels of 246 genes were decreased by \>1.5 fold in *Klf5* knockdown cells. Still, as pointed out, expression of many genes was unchanged or increased. The precise reason why MyoD binding was globally decreased while expression of many MyoD target genes was not decreased is not immediately clear. One possible explanation is that other MRFs, such as Myf5, compensate for the functional defect of MyoD, as recently published by Conerly M et al. (Dev Cell36:375, 2016). It is also possible that MyoD is dispensable for enhancer activity. Among the 753 MyoD-target genes depicted as red points in [Figure 4D](#fig4){ref-type="fig"}, expression of 55 genes was increased by \>1.5-fold, and 246 genes were decreased by \>1.5-fold. MyoD binding to regions proximal (+/- 1.5 kb of gene) to those upregulated and downregulated genes was similarly decreased in *Klf5* knockout cells (please see [Author response image 2A](#fig9){ref-type="fig"}). Interestingly, however, Klf5 binding to MyoD sites near MyoD-target genes upregulated by *Klf5* deletion was much lower than to sites near downregulated genes ([Author response image 2B](#fig9){ref-type="fig"}). This lesser association of Klf5 with MyoD-containing enhancers is also illustrated by the heatmap for Klf5 and MyoD binding around the center of the MyoD-binding sites ([Author response image 2C](#fig9){ref-type="fig"}). These results suggest that the enhancers near the upregulated MyoD-target genes are likely to be indirectly affected by the loss of *Klf5*, though the precise regulatory mechanisms affecting the enhancer activity are not immediately clear. Given our current findings demonstrating the mechanistic importance of Klf5 on MyoD recruitment, we feel exploring this further is beyond the scope of the present paper, and that these issues should be addressed in our future studies. We thank the reviewers for these constructive comments.10.7554/eLife.17462.022Author response image 2.(**A**) Histograms of MyoD tag densities at MyoD binding regions proximal to MyoD target genes that were upregulated or downregulated (\>1.5-fold) by *Klf5* deletion. (**B**) Klf5 binding to MyoD-binding regions proximal to MyoD-target genes whose expression was downregulated or upregulated by *Klf5* deletion. (**C**) Heatmaps for Klf5 and MyoD binding to MyoD-binding regions.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.022](10.7554/eLife.17462.022)

*Additional points:*

*6) Overall knockout and knockdown experiments were done with C2C12 cells. Please check that similar results are obtained using Klf5 KO primary myoblasts.*

We greatly appreciate the reviewer's valuable suggestions. We agree that the data obtained from primary satellite cells strengthen our observations. We have performed experiments with satellite cells isolated from*Pax7^CreERT2/+^;Klf5^flox/flox^*(satellite cell-specific *Klf5* knockout) and the control Pax7^+/+^;Klf5^flox/flox^mice. After treatment with 4OH-Tamoxifen to delete *Klf5*, *Pax7^CreERT2/+^;Klf5^flox/flox^*cells showed defective myogenic differentiation indicated by decreased Myogenin protein expression and decreased *Myog, Myl4* and *Myom2* mRNA expression. These results are now presented in [Figure 7](#fig7){ref-type="fig"}.

*7) For completeness the authors should verify that MEF2 protein is also unaffected in the setting of Klf5 deletion.*

As suggested we analyzed Mef2 protein levels. We have added new panel in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. Mef2 protein was not affected by *Klf5* deletion.

*8) The presence of other KLF family members might partially compensate for the differentiation defect of Klf5 KO cells. Please show data on the expression of other Klf gene family members during myogenic differentiation or at least discuss this further citing existing data. The authors mention KLF2/4 in the context of muscle fusion but there are others that have been linked to skeletal muscle biology and it is important to provide this background.*

We thank the reviewer for pointing out these important points. We performed qRT-PCR to detect expression of other Klf family members in *Klf5* knockdown and control cell on day 3. Levels of Klf6, Klf13, Klf15, and Klf16 expression were modestly, but significantly increased in Klf5 knockdown cells on day 3. On the other hand, expression of Klf10 and Klf11 was decreased in Klf5 knockdown cells ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

As pointed out, previous studies have shown that Klf members play diverse and important roles. This includes Klf15 in muscle biology. We have expanded the Introduction to better introduce Klfs in the field of muscle biology by citing a recent very excellent review by Prosdocimo DA and Jain MK et al. Trends Cardiovasc Med25, 278, 2015.

*9) The murine pictures ([Figure 1](#fig1){ref-type="fig"}) do not really appear to support the conclusions that are stated in the text and in the legend. The change in Klf5 expression does not appear to be very dramatic, nor is the small set of images shown without quantification sufficient to support the notion that Klf5 expression specifically increases with regeneration and concomitant with myogenin expression in vivo. More quantitation is necessary. The C2C12 data are much more clear.*

Although we show expression of Pax7 and Klf5 in a myoblast attached to an isolated myotube in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, the lack of images of a section of muscle in a steady state that corresponds to the images shown in [Figure 1](#fig1){ref-type="fig"} may make comparison unclear. In line with this, representative images of uninjured muscle sections were added to the revised [Figure 1B](#fig1){ref-type="fig"}. Klf5 was barely expressed in the quiescent satellite cells and in myonuclei in the intact muscle ([Figure 1B](#fig1){ref-type="fig"}, upper panel). We have also added a figure showing levels of Klf5 mRNA expression over the course of muscle regeneration. Klf5 expression was markedly increased along with Myogenic factors such as Pax7, Myod1, Myogenin and Myh3 during muscle regeneration ([Figure 1A](#fig1){ref-type="fig"}).

*10) In relation to [Figure 2](#fig2){ref-type="fig"}, It is stated in the text that no effect of tamoxifen is seen until 28 days without injury. It would appear critical to show the effect of losing KLF5 on normal muscle morphology at this time point. There is also no methodology described for how muscle size was quantified in terms of mouse number, sections examined etc., and there are no SDs shown on the graph. Given the heterogeneity in mouse injury from experiment to experiment, \"n of 3\" is a limited number to conclude that \"representative data\" are shown. In addition, no data are shown to verify that injury was similar at early time points in a set of control and Klf5 KO mice.*

We apologize for the insufficient description of the experimental methodology. Quantification of myofibers in immunostained tissue sections was performed as below: To analyze the distribution of fiber diameters, at least three individual sections from each of four *Pax7^CE/+^;Klf5^flox/flox^*and four or five (for day7 and 28, respectively) *Pax7~+/+~;Klf5~flox/flox~*(control) mice were examined. Immunofluorescent images of laminin were acquired, after which the area surrounded by laminin signal in each cross-section was quantified using Olympus cellSense Digital Imaging software. In each mouse, the diameters of 1000 (for CTX day 7) or 500 (for CTX day 28) regenerating fibers that had centrally located myonuclei were analyzed. This is now stated in the experimental procedure.

As pointed out, we observed certain histological differences among the mice in the same experimental group. However, the difference between wild-type and *Klf5* KO mice was clearly more pronounced than differences within the group. Muscle phenotypes after CTX-mediated injury, particularly the distribution of muscle diameters was similar among each group at each time point (day 7 and day 28). To better illustrate this, we show myofiber diameter in each mouse in [Author response image 3](#fig10){ref-type="fig"}. The graphs clearly show that in all three *Klf5* KO mice, the histogram of muscle diameters was shifted toward smaller diameters. Accordingly, we are confident that the muscle phenotypes we described are consistent across experiments.10.7554/eLife.17462.023Author response image 3.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.023](10.7554/eLife.17462.023)

We agree that number of animals (3) is relatively small for the muscle regeneration experiment (on day 28). We carried out the muscle regeneration experiment in another *Klf5* KO and control mice and found that muscle regeneration was markedly attenuated in *Klf5* KO mice on day 28. This result was added to the analysis of the distribution of fiber diameters and presented in [Figure 2F](#fig2){ref-type="fig"}.

We assessed the morphology of *Klf5*-deleted skeletal muscle using H&E staining on day 28 after injecting tamoxifen. This confirmed that no obvious morphological change or sign of degeneration was present on day 28 after loss of *Klf5*. This result is presented in the new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.

In addition, we assessed the injured muscle on day 4 after CTX injection to verify that the injury was similarly evoked in a set of control and *Klf5* KO mice at an early time point (revised [Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.17462.024Author response image 4.**DOI:** [http://dx.doi.org/10.7554/eLife.17462.024](10.7554/eLife.17462.024)

*11) The level of MHC expression by immunoblot ([Figure 3](#fig3){ref-type="fig"}) seems very low in the normal cells in comparison to the robust immunostaining. It is also surprising that no MHC is seen in the Klf5 KO cells, given the obvious (albeit reduced) MHC in the KO cells with immunostaining. This raises a concern about how representative the depicted blots are of MHC expression, a concern that is furthered by the clear expression of MHC in the KO cells on 3E. In addition, although the rescue of MHC expression by exogenous KLF5 in the CRISPR line is clear, it is also poor and incomplete and this should at least be discussed.*

We thank the reviewer for pointing out this important issue. We checked the specificity of the antibody for MHC and repeated the Western blot. New Western blot data with longer exposure is now provided in revised [Figure 3C](#fig3){ref-type="fig"}. It indicates that MHC protein is expressed but at a lower level in *Klf5* knockout C2C12 cells than in GFP-targeted control cells, which is in line with the result of the immunostaining.

As pointed out, exogenous KLF5 expression did not fully recapitulate MHC expression in the control cells. This insufficient rescue may be due to the differences between endogenous and exogenous Klf5, including expression levels and timing of Klf5 expression. In the control cells, for instance, Klf5 is transiently upregulated early during differentiation. However, this temporal regulation of Klf5 is lost in cell expressing exogenous Klf5. Although the precise mechanisms are not immediately clear, we added these possible mechanisms to the Discussion, as suggested.
